UBS Group
CELG

UBS Group’s Celgene Corp CELG Stock Holding History

UBS Group’s Portfolio CELG Stock Details CELG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-210,300
Closed -$20.9M – 8836
2019
Q3 		$20.9M Buy
210,300
+83,800
+66% +$7.96M 0.01% 1206
2019
Q2 		$11.7M Sell
126,500
-526,270
-81% -$50M ﹤0.01% 1621
2019
Q1 		$61.6M Buy
652,770
+175,400
+37% +$15.3M 0.03% 542
2018
Q4 		$30.6M Buy
477,370
+365,505
+327% +$27M 0.01% 832
2018
Q3 		$10M Sell
111,865
-251,040
-69% -$22.2M ﹤0.01% 1780
2018
Q2 		$28.8M Buy
362,905
+57,366
+19% +$4.76M 0.01% 951
2018
Q1 		$27.3M Buy
305,539
+221,539
+264% +$21.3M 0.01% 959
2017
Q4 		$8.77M Buy
84,000
+64,000
+320% +$7.22M ﹤0.01% 1834
2017
Q3 		$2.92M Sell
20,000
-75,600
-79% -$10.3M ﹤0.01% 2743
2017
Q2 		$12.4M Buy
95,600
+94,600
+9,460% +$11.6M 0.01% 1362
2017
Q1 		$124K Sell
1,000
-210,520
-100% -$25.2M ﹤0.01% 4954
2016
Q4 		$24.5M Buy
211,520
+143,215
+210% +$15.9M 0.01% 911
2016
Q3 		$7.14M Sell
68,305
-202,480
-75% -$21.9M ﹤0.01% 1693
2016
Q2 		$26.7M Buy
270,785
+206,785
+323% +$21.4M 0.02% 771
2016
Q1 		$6.41M Buy
64,000
+48,500
+313% +$4.99M ﹤0.01% 1659
2015
Q4 		$1.86M Sell
15,500
-1,100
-7% -$127K ﹤0.01% 2860
2015
Q3 		$1.79M Sell
16,600
-4,215
-20% -$523K ﹤0.01% 2834
2015
Q2 		$2.41M Sell
20,815
-38,800
-65% -$4.44M ﹤0.01% 2800
2015
Q1 		$6.87M Sell
59,615
-82,085
-58% -$9.81M ﹤0.01% 1786
2014
Q4 		$15.8M Buy
+141,700
New +$14.9M 0.01% 1154

Other funds holding CELG

FP
Factorial Partners Mt. Kisco, New York $138M AUM 25.59% 1-Year Est. Return
HCM
Howard Capital Management Roswell, Georgia $8.4B AUM 51.89% 1-Year Est. Return
PCMC
Private Capital Management (Colorado) Denver, Colorado $501M AUM 17.09% 1-Year Est. Return
WCG
Weaver Consulting Group Huntington Beach, California $488M AUM 17.59% 1-Year Est. Return

UBS Group's CELG Position: Q4 2019 in Review

UBS Group sold out of Celgene Corp (CELG) in Q4 2019, closing a stake of 2,164,145 shares — an estimated $215M sold.

UBS Group first reported a position in CELG in Q4 2014 and held it in 20 quarters. The position peaked at $489M in Q2 2017. 4 funds tracked by Wall St. Rank hold CELG as of Q4 2019.

  • UBS Group reported no remaining Celgene Corp position as of Q4 2019 after selling out during the quarter.
  • UBS Group sold 2,164,145 Celgene Corp shares in Q4 2019, an estimated $215M.
  • UBS Group first reported a position in Celgene Corp in Q4 2014 and held it in 20 quarters.
  • UBS Group's Celgene Corp position peaked at $489M in Q2 2017.
  • 4 funds tracked by Wall St. Rank held Celgene Corp as of Q4 2019.

Based on UBS Group's 13F filing for Q4 2019, filed 14 Feb 2020.